CCI
KYNB

Columbus Circle Investors’s Kyntra Bio KYNB Stock Holding History

Columbus Circle Investors’s Portfolio KYNB Stock Details KYNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-2,526
Closed -$2.99M – 191
2017
Q4 		$2.99M Sell
2,526
-40
-2% -$50.2K 0.06% 167
2017
Q3 		$3.45M Buy
+2,566
New +$2.7M 0.06% 187
2016
Q1 		– Sell
-5,687
Closed -$4.33M – 276
2015
Q4 		$4.33M Buy
+5,687
New +$3.77M 0.03% 229

Other funds holding KYNB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
HIM
Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Columbus Circle Investors's KYNB Position: Q1 2018 in Review

Columbus Circle Investors sold out of Kyntra Bio (KYNB) in Q1 2018, closing a stake of 2,526 shares — an estimated $2.99M sold.

Columbus Circle Investors first reported a position in KYNB in Q4 2015 and held it in 3 quarters. The position peaked at $4.33M in Q4 2015. 193 funds tracked by Wall St. Rank hold KYNB as of Q1 2018.

  • Columbus Circle Investors reported no remaining Kyntra Bio position as of Q1 2018 after selling out during the quarter.
  • Columbus Circle Investors sold 2,526 Kyntra Bio shares in Q1 2018, an estimated $2.99M.
  • Columbus Circle Investors first reported a position in Kyntra Bio in Q4 2015 and held it in 3 quarters.
  • Columbus Circle Investors's Kyntra Bio position peaked at $4.33M in Q4 2015.
  • 193 funds tracked by Wall St. Rank held Kyntra Bio as of Q1 2018.

Based on Columbus Circle Investors's 13F filing for Q1 2018, filed 9 May 2018.